Definitive Contract 75N91023C00009
Award Date
2/28/23
Potential Completion Date
10/31/24
Potential Value
$355K
Federal Agency
National Cancer Institute
Awardee
Petri Bio Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Torrance, CA 90501, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
17
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chimeron Bio Corporation, a small business manufacturer, for PHASE I THERAPEUTIC AWARD: CHIMERIC NANOPARTICLE DELIVERY OF AN SARNA-BASED CANCER VACCINE FOR FAMILIAL ADENOMATOUS POLYPOSIS under the Small Business Innovation Research (SBIR) Program. The contract is set aside for small businesses. This award is associated with a pre-solicitation opportunity that sought proposals...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
This is a Phase I SBIR contract award from the National Cancer Institute (NCI) to Tranquility Biodesign LLC, a small business, for the development of a novel engineered bacterial anticancer immunotherapy for Merkel cell carcinoma. The contract, valued at $354,996.00, was awarded under a total small business set-aside solicitation seeking proposals for the development of therapeutic, device, or diagnostic technologies for the treatment, detection, and diagnosis of pediatric cancers and rare...
This is a $1,997,803 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to Cell Microsystems Inc., a small business manufacturer of specialized biomedical research equipment and tools. The contract is for the topic "Integrated Imaging and Molecular Analysis of Glioblastoma Using SCOPE SEQ on the Air Flow" and has a total small business set-aside designation. The contract will support...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of "Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning" as described in the original solicitation. This Phase I SBIR contract has a period of performance from...
The National Cancer Institute (NCI) awarded a $353,102 Firm Fixed Price contract to Angstrom Research Inc., a self-certified small disadvantaged business, for a Phase I SBIR (Small Business Innovation Research) Concept Award. The contract, identified as 75N91024C00012, is part of the NCI's SBIR program and is focused on the development of innovative therapeutic technologies, devices, or diagnostics for the treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. This is a...
This firm fixed price definitive contract was awarded by the National Institutes of Health National Cancer Institute to Senti Biosciences, Inc., a self-certified small disadvantaged business, for $1,999,993. The contract addresses Topic 414 from the fiscal year 2021 Small Business Innovation Research Program solicitation issued by the Department of Health and Human Services, which sought proposals for synthetic biology gene circuits for cancer therapy. The place of performance is South San...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...